Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lidocaine/dibucaine CRPs

This article was originally published in The Tan Sheet

Executive Summary

Consumer Product Safety Commission will provide options to its commissioners on how to proceed with proposal to require child- resistant packaging for OTC lidocaine and dibucaine products in the near future, CPSC tells Nonprescription Drug Manufacturers Association during meeting May 25 at CPSC headquarters. One option, CPSC said, is that the reg is "technically feasible, practical and appropriate" and should be finalized. NDMA maintained that acceptable CRP technology for lidocaine/dibucaine products is not available and the cost necessary to develop it is too high in light of the small size of the market for those products. NDMA reiterated that adverse experiences from lidocaine/dibucaine do not warrant CRPs ("The Tan Sheet" Sept. 6, 1993, In Brief). CPSC said that it will take NDMA's complaints into account
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel